The pharmacology and mode of action of venlafaxine

Reviews in Contemporary Pharmacotherapy

Volumn 9, Issue 5, 1998, Pages 293-302

  Horst, W Dale ^a   Preskorn, Sheldon H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; CHOLINERGIC RECEPTOR; DOPAMINE; HISTAMINE RECEPTOR; NORADRENALIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ARTICLE; DOPAMINE BRAIN LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; PSYCHOPHARMACOLOGY; SEROTONIN BRAIN LEVEL;

EID: 0031820366     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Abdelmawla A, Bitsios P, Langley RW, Szabadi E, Bradshaw CM. Comparison of venlafaxine, desipramine and paroxetine on autonomic functions in man. J Psychopharmacol 1997a; 11 (Suppl): A28.
2. Abdelmawla A, Langley RW, Szabadi E, Bradshaw CM. Comparison of venlafaxine, desipramine and paroxetine on the dorsal hand vein in man. J Psychopharmacol 1997b; 11 (Suppl): A28.
3. Bitsios P, Langley RW, Szabadi E, Bradshaw CM. Comparison of venlafaxine, desipramine and paroxetine on the pupillary light reflex in man. J Psychopharmacol 1997; 11 (Suppl): A28.
4. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52:1023-1029.
5. Clement EM, Odontiadis J, Franklin M. Measurement of venlafaxine and its metabolite, oxydesmethylvenlafaxine, in human plasma using HPLC with coulometric detection. J Psychopharmacology 1997; 11 (Suppl): A36.
6. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 1994; 114: 559-565.
7. Daffner-Bugia C, Laakman G, Voderholtzer U et al. The neuroendocrine effects of venlafaxine in healthy subjects. Hum Psychopharmacol 1996; 11: 1-9.
8. Fabre LF, Putman HP. An ascending single-dose tolerance study of Wy-45,030, a bicyclic antidepressant, in healthy men. Curr Ther Res 1987; 42: 901-909.
9. Fava M, Rosenbaum JF, Cohen L et al. High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine. J Affect Disord 1992; 25: 229-234.
10. Franklin M, Campling G, Clement EM, Cowen PJ. Effect of venlafaxine on pineal metabolism and brain and pineal monoamines in the rat. J Psychopharmacol 1997; 11 (Suppl): A45.
11. Harvey AT, Preskorn SH. Mechanism of action of venlafaxine in normal male volunteers. Clin Pharmacol Ther 1997; 61: 175.
12. Haskins JT, Moyer JA, Muth EA, Sigg EB. DMI, Wy-45,030, Wy-45,881 and ciramadol inhibit locus coeruleus neuronal activity. Eur J Pharmacol 1985; 115: 139-146.
13. 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993; 23: 349-359.
14. Klamerus KJ, Maloney K, Rudolph RL et al. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992; 32: 716-724.
15. Laakmann G. Psychopharmacology and depression research. Berlin: Springer Verlag, 1990.
16. Laakmann G, Schuhmacher G, Benkert O, von Werder K. Stimulation of growth hormone by desipramine and clomipramine in man. J Clin Endocrinol Metab 1977; 44: 1010-1013.
17. Laakmann G, Guillery T, Benkert O, Eversmann T. Influence of nomifensine on growtth hormone, prolactin, luteinising hormone and thyreotropin in healthy subjects and hyperprolactinaemic patients. In: Obiols J, Ballus C, Monclus ED, Pujol J, eds. Biological psychiatry today. Amsterdam: Elsevier-North Holland, 1979: 705-710.
18. Laakmann G, Gugath M, Kuss HJ, Zygan K. Comparison of growth hormone and prolactin stimulation induced by chlorimipramine and desipramine in man in connection with chlorimipramine metabolism. Psychopharmacology 1984a; 82: 62-66.